Overview of Fibrous Dysplasia Market 2018-2023 | Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck & Co., Inc, Merrimack Pharmaceuticals Inc, Oncolys BioPharma Inc and Others

An expert on premium research reports, Market Research Future has added a report titled "Global Fibrous Dysplasia Market 2023" to its offering. The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.   

Market Scenario

The fibrous dysplasia market growth is majorly attributed to the increasing prevalence of the bone disorders. Moreover, some cases of fibrous dysplasia leads to cancer, which is likely to drive the market growth.

Fibrous dysplasia is a rare and chronic bone disorder in which fibrous tissue develops in place of normal bone, weakens the affected bone, and deform or fracture it. As per reports from The Johns Hopkins University, the exact cause of fibrous dysplasia is unknown, but it is believed to be due to a chemical irregularity in a specific bone protein. This bone protein abnormality may arise due to a gene mutation present at birth, although it is not known to be an inherited disorder.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4780

It often results in uneven growth of bones, pain, brittle bones, and bone deformity. In fibrous dysplasia, the most commonly affected bones includes femur (thighbone), tibia (shin bone), ribs, skull, facial bones, humerus (the bone of the upper arm), pelvis, vertebrae in the spine (less often).

Currently, no cure is available for fibrous dysplasia. However, present treatment methods helps to prevent complications, such as recurrent bone fractures to help make the condition less severe.

According to reports from International Osteoporosis Foundation, Each year an estimated 1.5 million individuals suffer a fracture due to bone disease. The risk of a fracture increases with age and is more in women. Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into developing countries and emerging economies.

However, high cost of the current treatment methods and lack of alternative methods for the treatment of fibrous dysplasia may slow the market growth during the forecast period.

The global fibrous dysplasia market is expected to grow at a CAGR of ~6.2 % during the forecast period 2017-2023.

Segmentations

The global fibrous dysplasia market is segmented on the basis by diagnosis, by treatment, and by end user.

On the basis of diagnosis, it is segmented into X-rays, CT scans, MRI, bone scan, biopsy, and others.  

On the basis of treatment, it is segmented into medications, surgical, and others. The medications is further segmented into bisphosphonates, intravenous (IV) pamidronate, calcitonin, raloxifene, and others

On the basis of the end user, it is segmented into hospitals & clinics, research centers, and others.

Regional Analysis

The Americas dominate the global fibrous dysplasia market owing to well-developed technology, increasing patient with bone disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global fibrous dysplasia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period.   

Asia Pacific is the fastest growing market owing to the presence of rapidly developing healthcare technology, increasing patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries such as India is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead to the use of advanced equipment, which, in turn, may increase the market growth of the fibrous dysplasia in the region.

On the other hand, the Middle East & Africa holds the least share of the global fibrous dysplasia market due to limited screening, ignorance of diseases, and poor access to treatment, especially, in African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 

Browse Complete 120 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/fibrous-dysplasia-market-4780

Key Players

Some of key the players in the market are Novartis AG, Pfizer Inc, Amgen Inc, AVEO Pharmaceuticals Inc, Bayer AG, Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck & Co., Inc, Merrimack Pharmaceuticals Inc, Oncolys BioPharma Inc, United Therapeutics Corp and others.

Detailed Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4 Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

...Continued! 

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/4780

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.